Combination of Darolutamide and Stereotactic Body Radiation Therapy in Patients With Castration Resistant Prostate Cancer and Oligometastases on Functional Imaging
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- UNICANCER
- 入组人数
- 336
- 试验地点
- 4
- 主要终点
- Radiographic Progression-free survival (rPFS)
研究概览
简要总结
In earlier stages of prostate cancer, male sexual hormones (androgens) stimulate the growth of cancer cells. Castration-resistant prostate cancer (CRPC) means that the prostate cancer continued to grow despite patients are taking hormone therapy to control the disease. One of the standard treatments for these patients is so-called 'new generation' hormonal therapy. These hormone therapies include apalutamide, enzalutamide, or darolutamide. They work by blocking androgen receptors that play an important role in the growth of prostate cancer.
In the case of oligometastatic CRPC, the cancer has gone beyond the prostate and has spread to other organs in the body (metastases), but these metastases remain limited in number.
An early detection of the oligometastatic CRPC and appropriate treatment may prolong survival in these patients.
The treatment proposed as part of this research is a combination of oral darolutamide, approved in Europe to treat patients with CRPC who do not have metastasis visible on CT-scan or bone scintigraphy (but visible with positron emission tomography-scan (PET-Scan), a more precise imaging technique) with stereotactic body radiotherapy (SBRT), a new radiotherapy technique guided by very high precision medical imaging. This method makes it possible to better target cancer cells while preserving neighboring healthy organs.
The principal objective of this trial is to evaluate the efficacy of the combination of SBRT with darolutamide, compared to darolutamide.
详细描述
PEACE 8 is a phase III open-label, randomised (patients are randomly assigned to treatment), international, multicentre trial, evaluating the benefit of adding SBRT to darolutamide for treating patients with oligometastatic CRPC.
Eligible patients will be randomised into either an experimental group receiving darolutamide + SBRT or a control group receiving darolutamide. In both arms, all patients will receive continuous castration (ADT) during the trial course.
Patients' participation in the trial will not exceed 60 months after randomisation, including a maximum treatment duration of 60 months and follow-up up to 60 months after randomisation.
After signing the consent form, patients will enter the pre-inclusion period (before the start of treatment), during which the investigator will carried out all the tests required to assess their eligibility, including demographic data collection, tumour evaluation, and clinical and biological assessments.
Patients will receive doralutamide until disease progression or unacceptable toxicity for a maximum of 5 years after the start of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.
- •Patients aged ≥18 years.
- •Patient with histologically confirmed of adenocarcinoma prostate cancer without small cell or pure endocrine features.
- •Patient with a history of local treatment with curative intent for localised prostate cancer, including surgery or radiotherapy.
- •Patients with castration resistant prostate cancer, defined as either:
- •An increasing PSA level, confirmed in 3 consecutive assessments performed at least 1 week apart. This despite androgen deprivation therapy and castrate levels of testosterone.
- •Tumour progression of soft tissue according to the response criteria in solid tumours (RECIST) version (v)1.
- •Tumour progression on bone scan, according to PCWG3 criteria.
- •N.B. The two latter conditions only apply to the M1CRPC population.
- •Detection of 1 to 5 metastatic sites (pelvic lymph nodes included) on new generation PET using either choline, fluciclovine, or PSMA as tracer.
- •All metastatic sites must be amenable to stereotactic radiation therapy.
- •Patient with normal haematological function: absolute neutrophil count (ANC) >1.0 x 10⁹/L, platelets count ≥100 x 10⁹/L, and haemoglobin ≥9.0 g/dL.
- •Patient with normal liver function with total bilirubin ≤1.5 upper limit of normal (ULN) (unless documented Gilbert's syndrome), aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤2.5 ULN (≤5 ULN in the presence of liver metastases).
- •Adequate liver function with bilirubin <3 mg/dL and albumin >2.5 g/dL.
- •Systolic blood pressure <160 mmHg and diastolic blood pressure <100 mmHg, as documented at baseline. Patients with hypertension are eligible if their hypertension is controlled and they meet all other eligibility criteria.
- •Adequate kidney function with a creatinine clearance >30 mL/min (Cockcroft-Gault).
- •Patient with Eastern Cooperative Oncology group (ECOG) performance status (PS) ≤
- •Patient is willing to use contraceptive during and for at least 1 week after discontinuing darolutamide.
- •Patient affiliated to the social security system (or equivalent according to local regulations for participation in clinical trials).
- •Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.
排除标准
- •Patient previously treated for metastatic prostate cancer with a novel hormonal agent (NHA), a CYP17 inhibitor, ketoconazole, chemotherapy, or immunotherapy.
- •A history of cancer, other than the prostate cancer under study, within the 3 years prior to study inclusion, excluding cured localised cancer such as non-melanomatous skin cancer and non-muscle invasive bladder cancer.
- •Presence of an uncontrolled disease or affection that according to the investigator will hinder compliance with the trial procedures or requires hospitalisation.
- •Known to have active viral hepatitis, active human immunodeficiency virus (HIV) A at screening.
- •Patients with known allergy or severe hypersensitivity to the study treatment or any of its excipients.
- •Inability to swallow oral medications.
- •Gastrointestinal disorder or procedure that can be expected to interfere significantly with the absorption of study treatment.
- •Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV.
- •Patients participating in another therapeutic trial within the 30 days prior to randomisation.
- •Patients unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial.
- •Person deprived of their liberty or under protective custody or guardianship.
研究组 & 干预措施
ADT + darolutamide
Up to 5 years of treatment
干预措施: Darolutamide 300 mg (Drug)
ADT + darolutamide
Up to 5 years of treatment
干预措施: Androgen deprivation therapy (Drug)
ADT + darolutamide + SBRT
Up to 5 years of treatment
干预措施: Darolutamide 300 mg (Drug)
ADT + darolutamide + SBRT
Up to 5 years of treatment
干预措施: Stereotactic body radiation therapy (Radiation)
ADT + darolutamide + SBRT
Up to 5 years of treatment
干预措施: Androgen deprivation therapy (Drug)
结局指标
主要结局
Radiographic Progression-free survival (rPFS)
时间窗: From randomization to disease progression or death, up to 5 years.
The radiographic Progression-free survival is defined as the time interval between the randomisation and radiographic disease progression with conventional imaging (CT-scan or bone-scan), or death due to any cause, whichever occurs first.
次要结局
- Time to treatment failure (TTF)(From randomization to discontinuation of darolutamide, up to 5 years)
- Biochemical response rate(Throughout study completion, up to 5 years.)
- Overall survival (OS)(From randomization to death from any cause, up to 5 years.)
- Prostate cancer-specific survival(From randomization to death due to prostate cancer, up to 5 years.)
- Time to PSA progression(From randomization to PSA progression, up to 5 years.)
- Time to next symptomatic skeletal event (SSE)(Time from randomization to the first symptomatic skeletal event, up to 5 years.)
- Time to pain progression(Time from randomization to the first occurence of pain progression, up to 5 years.)
- Safety/tolerance(Throughout study completion, up to 5 years.)
- Functional Assessment of CAncer Therapy - Prostate (FACT-P)(At baseline, 1 month, every 4 months during treatment period, and at the end of treatment (up to 5 years).)
- Brief Pain Inventory - Short Form (BP-SFI) questionnaire(At baseline, 1 month, every 4 months during treatment period, and at the end of treatment (up to 5 years).)